BRKR at a glance
Bruker Corp (BRKR, SEC CIK 1109354) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 14, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Bruker Corp (BRKR) reported revenue of $3.4 billion (up 2.1% from FY2024) and a net loss of $8.6 million. Diluted EPS was -$0.15.
- As of June 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Bruker Corp (BRKR) shares worth $3.9 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Munch Mark on September 15, 2026 of 2,000 shares at $52.87 per share.
- In the last 90 days, BRKR insiders reported 0 open-market purchases ($0) and 4 open-market sales ($539K) on Form 4, a net sale of $539K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.4B
- +2.1% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$539K
- 13F holders
- 33 funds
- $3.9B · +0 vs prior quarter
- Latest 10-Q
- Aug 5, 2026
- Quarterly report
SignalX for BRKR
Don't miss the next BRKR filing
- Alerts as it files. A push when BRKR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BRKR, by share count.
- Ask anything. An AI agent that reads every BRKR filing and answers with sources.
BRKR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Munch Mark | M | Sep 15, 2026 | 2,000 | - |
| Munch Mark | Sell | Sep 15, 2026 | 2,000 | $52.87 |
| Munch Mark | M | Sep 15, 2026 | 2,000 | $22.19 |
| Pusch Wolfgang | Sell | Aug 17, 2026 | 3,473 | $56.90 |
| Srega Juergen | A | Aug 15, 2026 | 16,898 | - |
| Prause Burkhard | A | Aug 15, 2026 | 2,678 | - |
| Munch Mark | F | Aug 15, 2026 | 2,984 | $57.70 |
| Srega Juergen | A | Aug 15, 2026 | 13,698 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $3.4B | $3.4B |
| Gross Profit | - | $1.6B | $1.6B |
| Operating Income | - | $253.1M | $68.2M |
| Net Income | - | $113.1M | -$8.6M |
| Gross Margin | - | 49.0% | 45.9% |
| Op. Margin | - | 7.5% | 2.0% |
| Net Margin | - | 3.4% | -0.3% |
| Balance Sheet | |||
| Total Assets | $4.2B | $5.8B | $6.2B |
| Equity | $1.4B | $1.8B | $2.5B |
| ROE | - | 6.3% | -0.4% |
| Per Share | |||
| EPS | - | $0.76 | $-0.15 |
| Cash Flow | |||
| Operating CF | - | $251.3M | $134.1M |
| CapEx | - | $115.3M | $90.8M |
Source: XBRL data in Bruker Corp (BRKR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BRKR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 33 | $3.92B |
| Q1 2026 | 33 | $2.16B |
| Q4 2025 | 29 | $2.62B |
| Q3 2025 | 30 | $1.71B |
| Q2 2025 | 31 | $2.17B |
| Q1 2025 | 28 | $1.74B |
| Q4 2024 | 22 | $2.14B |
| Q3 2024 | 19 | $781.8M |
- FMR LLC (Fidelity)+4.14M (+26%)
- AQR Capital Management+1.22M (+94%)
- Goldman Sachs Group+583.1K (+104%)
- Franklin Resources+310.2K (+11%)
- Dimensional Fund Advisors+268.5K (+11%)
- Two Sigma Investments−503.3K (-82%)
- Ameriprise Financial−386.1K (-80%)
- JPMorgan Chase & Co−112.1K (-25%)
- Invesco Ltd−53.9K (-18%)
- Raymond James Financial−38.2K (-15%)
- Viking Global Investors+893.5K
- Bridgewater Associates LP+42.3K
- Millennium Management−1.49M
- Blackstone Group−18.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 225 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
- ILMN · Illumina IncLaboratory Analytical Instruments
BRKR SEC filings: frequently asked questions
Are BRKR insiders buying or selling?
In the last 90 days, Bruker Corp (BRKR) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $539,054 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BRKR stock?
As of June 30, 2026, the largest Bruker Corp (BRKR) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($1.2 billion), BlackRock ($686.5 million), Vanguard Portfolio Management LLC ($294.2 million), Vanguard Capital Management LLC ($292.4 million), State Street Corp ($241.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BRKR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Bruker Corp (BRKR) reported revenue of $3.4 billion (up 2.1% from FY2024) and a net loss of $8.6 million. Diluted EPS was -$0.15. The figures come from the XBRL data in the 10-K.
What are the latest BRKR SEC filings?
Bruker Corp (BRKR) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 14, 2026 and a Form 4 insider filing on September 16, 2026.
What is BRKR's SEC CIK number?
Bruker Corp (BRKR)'s SEC Central Index Key (CIK) is 1109354. EDGAR lists every BRKR filing under that number.
Ask anything about BRKR
The research agent reads BRKR's filings, financials, insider trades and 13F holders, then answers with sources.